Dr Michael Irizarry (Eisai)

  • monoclonal antibody_Alzheimer’s
    Article

    Learning from lecanemab: a breakthrough treatment

    2023-03-06T19:00:59

    Here, Dr Michael Irizarry, Eisai’s Senior Vice President of Clinical Research and Deputy Chief Clinical Officer for Alzheimer’s Disease and Brain Health discusses its highly anticipated Alzheimer’s drug, lecanemab.